ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
94,183.30
-0.54%
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs Yen
157.695
0.00%
Brent Oil
79.285
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. MoonLake Immunotherapeutics (MLTX)

  7. MoonLake Immunotherapeutics (MLTX) ニュース

MLTX

MoonLake Immunotherapeut... (MLTX)

MoonLake Immunotherapeutics
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MLTX
日付受信時刻ニュースソース見出しコード企業名
2025/01/0821 : 00GlobeNewswire Inc.MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabNASDAQ:MLTXMoonLake Immunotherapeutics
2024/12/1906 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/1322 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721 : 05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/11/0721 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
2024/10/0905 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/09/1120 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/09/0920 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11NASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/08/0721 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11NASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/1105 : 40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/1021 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0806 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0806 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0805 : 59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0805 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
2024/06/0620 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/1621 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721 : 02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0721 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
2024/05/0720 : 57Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MLTXMoonLake Immunotherapeutics
2024/04/1020 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions NASDAQ:MLTXMoonLake Immunotherapeutics
2024/04/1020 : 00Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/1121 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/1101 : 00GlobeNewswire Inc.MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayNASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/0422 : 00GlobeNewswire Inc.MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024NASDAQ:MLTXMoonLake Immunotherapeutics
2024/03/0109 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
 Showing the most relevant articles for your search:NASDAQ:MLTX

最近閲覧した銘柄

NYSE
VZ
Verizon Communications
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
USOTC
ADDYY
Adidas (QX)
NYSE
BAC
Bank of America
NYSE
MRK
Merck
NYSE
XOM
Exxon Mobil
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
NYSE
AXP
American Express
FX
USDGBP
US Dollar vs Sterling
NASDAQ
NVDA
NVIDIA
FX
USDJPY
US Dollar vs Yen
NASDAQ
AAPL
Apple
COIN
SOLUSD
Solana
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有